ABSTRACT
The Sporopachydermia cereana species lives in decaying stems of cactus and is exceptionally rare as a human pathogen. A 57-year-old man with therapy-refractory acute promyelocytic leukaemia developed severe neutropaenia. After about 3 weeks of micafungin used as prophylaxis, he developed high fever, multiple pulmonary nodular infiltrates and a painful leg lesion. Blood culture yielded a yeast which was not identified by the Vitek 2 system. On ITS1-5.8S-ITS2 gene sequencing, the isolate was identified as S. cereana. Antifungal sensitivity by the Etest showed that the minimum inhibitory concentration for fluconazole was 0.75 µg/mL, and for anidulafungin, it was >32 µg/mL. He responded to liposomal amphotericin B but later died of Escherichia coli septicaemia. There were no cactus plants in the vicinity, suggesting that S. cereana might have alternative habitats.
Subject(s)
Antifungal Agents/therapeutic use , Chemoprevention/methods , Echinocandins/therapeutic use , Fungemia/diagnosis , Leukemia, Promyelocytic, Acute/complications , Lipopeptides/therapeutic use , Opportunistic Infections/diagnosis , Saccharomycetales/isolation & purification , DNA, Fungal/chemistry , DNA, Fungal/genetics , DNA, Ribosomal/chemistry , DNA, Ribosomal/genetics , DNA, Ribosomal Spacer/chemistry , DNA, Ribosomal Spacer/genetics , Escherichia coli Infections/complications , Escherichia coli Infections/diagnosis , Fatal Outcome , Fungemia/complications , Fungemia/microbiology , Fungemia/pathology , Humans , Immunocompromised Host , Male , Micafungin , Microbial Sensitivity Tests , Middle Aged , Neutropenia/complications , Neutropenia/diagnosis , Opportunistic Infections/complications , Opportunistic Infections/microbiology , Opportunistic Infections/pathology , Radiography, Thoracic , Saccharomycetales/classification , Saccharomycetales/genetics , Sepsis/complications , Sepsis/diagnosis , Sequence Analysis, DNA , Skin/pathology , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Invasive fungal disease (IFD) is an important problem complicating the therapy of haematologic patients. AIM: This study aimed to provide data on the epidemiology of IFD in an Asian teaching hospital, as well as the prescription practice of antifungal drugs. METHOD: We conducted a retrospective review of 275 haematologic patients who were prescribed antifungal drugs in a 4-year period (2007-2010), of whom 130 (47%) had undergone haematopoietic stem cell transplantation. RESULTS: Antifungal prophylaxis with either fluconazole or itraconazole was given in 214 patients (78%). There were 414 prescriptions of antifungal drugs (including liposomal amphotericin B, voriconazole, caspofungin, micafungin, anidulafungin), of which 361 prescriptions were empirical. There were 14 patients with proven IFD, 11 of whom had breakthrough infection while on itraconazole prophylaxis. Interestingly, seven of these cases were due to infection by itraconazole-sensitive candida. CONCLUSION: These results provide important epidemiologic data necessary for the formulation of strategies for prevention and treatment of IFD in Asian patients.
Subject(s)
Antifungal Agents/therapeutic use , Hematologic Diseases/drug therapy , Hematologic Diseases/epidemiology , Hospitals, Teaching/trends , Mycoses/drug therapy , Mycoses/epidemiology , Adult , Aged , Aged, 80 and over , Asia/epidemiology , Female , Hospitals, Teaching/methods , Hospitals, University/trends , Humans , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
Eighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P<0.01). Acute GVHD had a significant negative impact on OS (P=0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT.